Guardant Health stock
Price history
+50.31% over the period1 year: from $96.48 (November 17, 2025) to $145.02 (November 16, 2026), +50.31%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $145.02 |
| October 30, 2026 | $178.80 |
| September 30, 2026 | $178.36 |
| August 31, 2026 | $159.02 |
| July 31, 2026 | $161.99 |
| June 30, 2026 | $150.03 |
| May 29, 2026 | $129.69 |
| April 30, 2026 | $87.08 |
| March 31, 2026 | $92.37 |
| February 27, 2026 | $93.90 |
| January 30, 2026 | $114.04 |
| December 31, 2025 | $102.14 |
| November 28, 2025 | $108.42 |
| November 17, 2025 | $96.48 |
At a glance
The company
Precision oncology company providing blood and tissue tests for cancer detection, profiling and research
Latest results
Quarter to September 30, 2026 · EPS -$0.29 (estimate -$0.75)
TickerLandia's take on Guardant Health
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−24.09% from the 52-week high
Analysts · 26 analysts
Average target$200.76+38.44% vs. price
Buy 25 · Hold 0 · Sell 1 · Strong buy
TickerLandia Fingerprint: Guardant Health
Compared with similar companies: very low earnings stability.
Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.
Profitabilitylow37
How much it earns on revenue and capital.
Metric Value Position in group Operating margin −39.4% 2 Gross margin 65.2% 83 Net margin −37.9% 2 ROA −19.9% 2 ROE 171.6% 98 Earnings stabilityvery low6
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 32.4% 6 Loss-making yearscounts in reverse: lower means more earnings stability 5 of 5 annual reports 6 Growthhigh75
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +36.10% 87 Average revenue growth (3 years) +29.75% 91 Earnings growth (year over year) +12.34% 46 Financial strengthhigh66
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 3.60 98 Debt/equitycounts in reverse: lower means more financial strength · negative shareholders' equity −7.61 98 Interest coverage −112.0 2 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong77
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −1.93% 42 Relative strength (6 months) +51.66% 95 1-year return +61.16% 92 Distance from 200-day average +14.24% 79 Riskhigh70
How much the price swings.
Metric Value Position in group Beta (1 year) 1.33 74 Volatility (60 days) 49.5% 76 Maximum drawdown (12 months) 33.0% 59
1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
How Guardant Health is valued
Compared with 11 similar companies
| Metric | Guardant Health | Position in the group | Band |
|---|---|---|---|
| Operating margin | -39.4% | Low | |
| ROE | 171.6% | High | |
| Debt/equity | -7.61 | Low | |
| Net margin | -37.9% | Low | |
| Price/sales | 16.0 | High |
Grey band: the middle half of the group; tick: the median; dot: Guardant Health. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$334.98M
Latest quarter · Q2 2026
Net income
-$120.14M
Latest quarter · Q2 2026
Quarterly net margin
-35.9%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $20.52B
- EPS
- -$3.68
- Volume
- 1.29M
- Daily trading
- €336.2M
- Dividend yield
- 0.00%
How Guardant Health is changing
All resultsRevenue grew 27.9% a year on average over the last 5 years
Operating margin rose from −121.1% to −44.4%
Shares outstanding up 28.6% in 5 years
Returns
Guardant Health returns
$1,000 invested in Guardant Health 5 years ago, on November 16, 2021, would be worth $1,378 today: +37.81% in total, +6.63% per year. This is the price return only: dividends are excluded.
| Period | Guardant Health | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −8.56% | −3.12% | $914 |
| 6 months | +52.78% | +2.07% | $1,528 |
| Year to date | +41.98% | +10.46% | $1,420 |
| 1 year | +50.31% | +13.33% | $1,503 |
| 3 years | +548.57% | +67.73% | $6,486 |
| 5 years | +37.81% | +60.86% | $1,378 |
Over the last 6 months it has done better than 88% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Guardant Health: technical analysis
Guardant Health shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 22.5% below its all-time closing high ($187.22, October 5, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 35
- Between 30 and 70
- vs 200-session average
- +9.09%
Support and resistance
Price areas where Guardant Health has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$184.77+27.41%2 touches, last on October 28, 2026
- Resistance$173.94+19.94%4 touches, last on August 26, 2026
- Resistance$154.16+6.30%4 touches, last on October 19, 2026
- Last price$145.02
- Support$135.23−6.75%3 touches, last on November 6, 2026
- Support$122.83−15.30%3 touches, last on June 17, 2026
- Support$114.53−21.02%4 touches, last on February 20, 2026
Volatility and risk
Over the last year it has moved more than the S&P 500.
- Beta (1 year) vs S&P 500
- 1.35
- Volatility (60 sessions, annualised)
- 50.1%
- Largest fall in the last year
- −32.98%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Guardant Health: seasonality
Average monthly price change over 8 years
Over the last 8 years, the strongest month for Guardant Health has been November: +13.04% on average, positive in 6 years out of 8. The weakest has been December: −6.65% on average, positive in 4 years out of 8.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +7.11% | +9.48% | 5 of 8 |
| February | +3.42% | −5.03% | 2 of 8 |
| March | −2.28% | +0.04% | 4 of 8 |
| April | −2.26% | −4.74% | 3 of 8 |
| May | +11.84% | +17.40% | 5 of 8 |
| June | +9.13% | +9.43% | 6 of 8 |
| July | +5.50% | +8.42% | 6 of 8 |
| August | +7.07% | −0.03% | 4 of 8 |
| September | −4.24% | −4.55% | 3 of 8 |
| October | +2.69% | −4.60% | 3 of 8 |
| November | +13.04% | +9.24% | 6 of 8 |
| December | −6.65% | −2.12% | 4 of 8 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Guardant Health and its competitors
Founded in 2011 and based in Palo Alto, California, the company focuses on precision oncology, analyzing DNA from blood and tumor samples to support cancer care and research. Its Guardant360 tests profile tumors for clinicians, the Guardant Reveal test detects cancer through circulating tumor DNA, and the Shield blood test screens adults for colorectal cancer. For drug developers and biopharmaceutical customers it offers the GuardantINFINITY and GuardantOMNI assays, the GuardantConnect software, and development services that range from companion diagnostics to clinical study support and kit delivery.
- Headquarters
- Palo Alto, United States
- Employees
- 2,490
- Founded
- 2011
- Chief executive
- Dr. Helmy Eltoukhy Ph.D.
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Guardant HealthGH | $20.52B | -39.4% | — | +52.78% |
| Medpace HoldingsMEDP | $19.12B | 21.4% | 38.0 | +57.36% |
| RevvityRVTY | $17.84B | 16.3% | 70.5 | +59.49% |
| Charles River Laboratories InternationalCRL | $16.19B | 14.3% | 367.4 | +123.10% |
| Quest DiagnosticsDGX | $28.56B | 14.9% | 25.9 | +40.23% |
| ICON PublicICLR | $14.58B | 2.7% | 77.9 | +63.31% |
Same industry or related industries, similar size. Compare Guardant Health with its competitors · Full profile
